Sonoscape Medical300633.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Sonoscape Medical (300633.SZ) trades at a P/E of 48.50x, P/B of 2.64x, P/S of 3.78x, and a dividend yield of 0.96%.
Longitudinal percentile comparison: P/E sits at the 26th percentile over the trailing 10Y window (vs. 36th percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 7th percentile over 3Y); P/S sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 58th percentile within its industry and the 60th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.96%, ranking at the 90th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 24.1 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Sonoscape Medical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300633 · SZSE: 300633 · 300633
Want the full picture on whether Sonoscape Medical (300633.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 48.50 | ||||||
| P/B (MRQ) | 2.64 | ||||||
| P/S (TTM) | 3.78 | ||||||
| Dividend Yield | 0.96% | ||||||
| Buyback + Div Yield | 0.96% |